Literature DB >> 12445194

Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain.

SilkeC Hofmann1, Sybille Thoma-Uszynski, Thomas Hunziker, Philippe Bernard, Corinna Koebnick, Angelika Stauber, Gerold Schuler, Luca Borradori, Michael Hertl.   

Abstract

Bullous pemphigoid, the most common autoimmune subepidermal bullous disorder, is associated with autoantibodies targeting antigenic sites clustered within the extracellular domain of BP180. To investigate epitope and subclass specificity of autoantibodies in bullous pemphigoid, we developed an enzyme-linked immunosorbent assay utilizing baculovirus-expressed recombinant forms of the NH2- and COOH-terminal regions of the extracellular domain of BP180 and examined sera obtained from patients with active bullous pemphigoid (n=116) and controls (n=100). Ninety-three (80%) and 54 (47%) of the 116 bullous pemphigoid sera recognized the NH2- and COOH-terminal regions, respectively, of the extracellular domain of BP180. Detailed analysis demonstrates that (i) this novel enzyme-linked immunosorbent assay is highly specific (98%) and sensitive (93%) as 108 of 116 bullous pemphigoid sera reacted with at least one of the baculovirus-derived recombinants, (ii) in active bullous pemphigoid, autoantibodies against the NH2-terminus of the extracellular domain of BP180 were predominantly of the IgG1 class, whereas a dual IgG1 and IgG4 response to this region was related to a more severe skin involvement, (iii) autoreactivity against both the NH2- and COOH-terminal regions was more frequently detected in patients with mucosal lesions, and (iv) levels of IgG (and IgG1) against the NH2-terminal, but not against the COOH-terminal portion of the extracellular domain of BP180, reflected disease severity indicating that autoantibodies against the NH2-terminus are critical in the pathogenesis of bullous pemphigoid. In conclusion, this novel enzyme-linked immunosorbent assay represents a highly sensitive and specific assay for rapid diagnosis of bullous pemphigoid and related disorders and may provide predictive parameters for the management of bullous pemphigoid patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445194     DOI: 10.1046/j.1523-1747.2002.19529.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  35 in total

1.  [A severe course of bullous pemphigoid in a young man].

Authors:  S Eigelshoven; D Bruch-Gerharz; E Enderlein; T Ruzicka; A S Büchau; M Hertl; J Reifenberger; K-W Schulte
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

Review 2.  Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.

Authors:  K A N Messingham; H M Holahan; J A Fairley
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

3.  Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid.

Authors:  Kelly N Messingham; Jeffrey W Wang; Heather M Holahan; Rupasree Srikantha; Samantha C Aust; Janet A Fairley
Journal:  Exp Dermatol       Date:  2015-11-23       Impact factor: 3.960

Review 4.  [Bullous pemphigoid: diagnosis and therapy].

Authors:  Andrea Kneisel; Michael Hertl
Journal:  Wien Med Wochenschr       Date:  2014-07-31

Review 5.  T cell control in autoimmune bullous skin disorders.

Authors:  Michael Hertl; Rüdiger Eming; Christian Veldman
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

6.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

7.  A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.

Authors:  Kelly A N Messingham; Megan H Noe; Marisa A Chapman; George J Giudice; Janet A Fairley
Journal:  J Immunol Methods       Date:  2009-05-05       Impact factor: 2.303

8.  IgG4 autoantibodies are inhibitory in the autoimmune disease bullous pemphigoid.

Authors:  Yagang Zuo; Flor Evangelista; Donna Culton; Antonio Guilabert; Lin Lin; Ning Li; Luis Diaz; Zhi Liu
Journal:  J Autoimmun       Date:  2016-07-01       Impact factor: 7.094

9.  Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay.

Authors:  Janet A Fairley; Matthew Bream; Colleen Fullenkamp; Sergei Syrbu; Mei Chen; Kelly N Messingham
Journal:  J Am Acad Dermatol       Date:  2012-10-18       Impact factor: 11.527

Review 10.  Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review.

Authors:  Xinyi Chen; Wenlin Zhao; Hongzhong Jin; Li Li
Journal:  Front Med (Lausanne)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.